MCID: CRV012
MIFTS: 19

Cervical Verrucous Carcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Cervical Verrucous Carcinoma

MalaCards integrated aliases for Cervical Verrucous Carcinoma:

Name: Cervical Verrucous Carcinoma 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3743
NCIt 47 C40190
UMLS 69 C1516435

Summaries for Cervical Verrucous Carcinoma

MalaCards based summary : Cervical Verrucous Carcinoma is related to verrucous carcinoma and cervicitis. An important gene associated with Cervical Verrucous Carcinoma is MAPK8IP2 (Mitogen-Activated Protein Kinase 8 Interacting Protein 2). The drugs Cisplatin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and liver.

Related Diseases for Cervical Verrucous Carcinoma

Diseases related to Cervical Verrucous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 verrucous carcinoma 10.0
2 cervicitis 10.0

Symptoms & Phenotypes for Cervical Verrucous Carcinoma

Drugs & Therapeutics for Cervical Verrucous Carcinoma

Drugs for Cervical Verrucous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
3
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
5
Bleomycin Approved Phase 3 11056-06-7 5360373
6
Levoleucovorin Approved Phase 3 68538-85-2
7
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
8
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
9
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
10
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
11
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
12
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
13
Doxepin Approved Phase 3 1668-19-5 667477 667468
14
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
15
Bevacizumab Approved, Investigational Phase 3,Phase 1,Phase 2 216974-75-3
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 143 6006
18
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
21 Antimetabolites Phase 3,Phase 2,Phase 1
22 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
23 Antimitotic Agents Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
25 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
26 Autonomic Agents Phase 3,Phase 2
27 Neurotransmitter Agents Phase 3,Phase 2
28 Peripheral Nervous System Agents Phase 3,Phase 2
29 Antibodies Phase 3,Phase 2,Phase 1
30 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
31 Immunoglobulins Phase 3,Phase 2,Phase 1
32 Antidotes Phase 3
33 Antirheumatic Agents Phase 3
34 Calcium, Dietary Phase 3
35
Cobalt Phase 3 7440-48-4 104729
36 Dermatologic Agents Phase 3,Phase 2
37 Folic Acid Antagonists Phase 3,Phase 1,Phase 2
38 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
39 Protective Agents Phase 3,Phase 2
40 Vitamin B Complex Phase 3,Phase 2,Phase 1
41 Cholinergic Agents Phase 3
42 Antifungal Agents Phase 2, Phase 3,Phase 1
43 Anti-Infective Agents Phase 2, Phase 3,Phase 1
44 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
45 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
46 Hormone Antagonists Phase 2, Phase 3
47 Hormones Phase 2, Phase 3,Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
49 Steroid Synthesis Inhibitors Phase 2, Phase 3
50 Antineoplastic Agents, Hormonal Phase 3

Interventional clinical trials:

(show top 50) (show all 127)

id Name Status NCT ID Phase Drugs
1 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
2 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
3 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
4 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
5 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
6 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
7 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
8 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
9 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
10 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Recruiting NCT00956007 Phase 3
11 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
12 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
13 CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy Withdrawn NCT01545687 Phase 3
14 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
15 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00833261 Phase 2 cetuximab;cisplatin
16 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
17 Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Unknown status NCT00721513 Phase 2 cisplatin;docetaxel;fluorouracil
18 Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Unknown status NCT00625937 Phase 2 cisplatin;docetaxel;tegafur-gimeracil-oteracil potassium
19 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
20 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2 Soy Isoflavones
21 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
22 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
23 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
24 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2 ispinesib
25 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
26 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2 Temsirolimus
27 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
28 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
29 Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00639769 Phase 2 cisplatin;irinotecan hydrochloride
30 Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck Completed NCT00720304 Phase 2 docetaxel;erlotinib hydrochloride
31 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
32 Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery Completed NCT00738868 Phase 2
33 Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery Completed NCT01333085 Phase 1, Phase 2 carboplatin;RAD001;paclitaxel
34 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
35 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
36 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
37 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
38 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
39 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
40 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
41 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
42 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
43 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
44 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
45 Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions Recruiting NCT01414426 Phase 2 vandetanib
46 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Recruiting NCT02734537 Phase 2 Cisplatin
47 Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting NCT02035527 Phase 1, Phase 2 sorafenib tosylate;cisplatin;docetaxel
48 Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck Active, not recruiting NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
49 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Active, not recruiting NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
50 PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120

Search NIH Clinical Center for Cervical Verrucous Carcinoma

Genetic Tests for Cervical Verrucous Carcinoma

Anatomical Context for Cervical Verrucous Carcinoma

MalaCards organs/tissues related to Cervical Verrucous Carcinoma:

39
Lung, Brain, Liver, Breast, Kidney, Endothelial, Colon

Publications for Cervical Verrucous Carcinoma

Articles related to Cervical Verrucous Carcinoma:

id Title Authors Year
1
Cytology of uterine cervical verrucous carcinoma. ( 18936012 )
2008
2
Combined ultrasound and magnetic resonance imaging findings on cervical verrucous carcinoma with endometrial invasion: a case report. ( 17583251 )
2007
3
Cervical verrucous carcinoma involving endometrium. Case report. ( 10422679 )
1999

Variations for Cervical Verrucous Carcinoma

Expression for Cervical Verrucous Carcinoma

Search GEO for disease gene expression data for Cervical Verrucous Carcinoma.

Pathways for Cervical Verrucous Carcinoma

GO Terms for Cervical Verrucous Carcinoma

Sources for Cervical Verrucous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....